Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
884.6 INR | -0.75% | -0.83% | +16.64% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.5 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.64% | 2.1B | C+ | ||
+48.79% | 781B | C+ | ||
+41.76% | 639B | B | ||
+19.43% | 330B | B- | ||
+7.18% | 293B | C+ | ||
+17.60% | 248B | B+ | ||
-0.41% | 221B | A+ | ||
+11.54% | 217B | B- | ||
+4.53% | 162B | C+ | ||
-3.92% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- APLLTD Stock
- Ratings Alembic Pharmaceuticals Limited